Table 2.

Preoperative chemotherapy delivery^*

Preoperative chemotherapy timing and delivery	Target interval (weeks)	Achieved interval (weeks) average ± SD	Number of cases, %
Onset of chemotherapy†
Interval from last radiation treatment to day 1, cycle 1 of chemotherapy	1.6–2.6	2.3 ± 0.6	2 (2.5%)‡
Number of cases delayed ≥2 weeks beyond target‡
Delivery of chemotherapy†
Duration: Interval from day 1, cycle 1 to day 1, last cycle chemotherapy	6	6.4 ± 1.2	9 (12%)§
Number of cases delayed ≥2 weeks beyond target duration
Dose: Number of cases with chemotherapy dose reduction			19 (24%)
Number of cases with dose reduction and/or any delay (1 week delay alone allowed for first instance of grade 3 neutropenia)			35 (44%)
Timing of surgery‖
Interval from day 1, last cycle chemotherapy to surgery	4–9	7.7 ± 2.8	4 (5%)§
Number of cases delayed ≥2 weeks beyond target from last cycle chemotherapy to surgery
Interval from day 1 radiation therapy to surgery	13–18	17.3 ± 2.9	8 (11%)§
Number of cases delayed ≥2 weeks beyond target from day 1 radiation therapy to surgery

^*All dose reductions or delays were caused by morbidity and were required by protocol.

^†Number of evaluable patients for chemotherapy delivery = 79 (see text).

^‡Neither instance of delayed chemotherapy was caused by radiation therapy morbidity. One case was delayed by port site infection. Another case was delayed for the patient to recover after coronary stent placement (asymptomatic cardiac disease, detected on stress test).

^§Includes 1 patient who completed 4 cycles of full-dose FOLFOX (5-fluorouracil, oxaliplatin, leucovorin) on schedule, was found to still have unresectable disease, and therefore received additional chemotherapy before undergoing surgery (see text).

^‖Number of evaluable patients for surgery = 76 (see text).